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Gas-2 like 2The A2A adenosine receptor (A2AR) is a G-protein-coupled receptor that contains a long cytoplasmic carboxyl
terminus (A2AR-C). We report here that Gas-2 like 2 (G2L2) is a new interacting partner of A2AR-C. The interac-
tion between A2AR and G2L2 was veriﬁed by GST pull-down, co-immunoprecipitation, immunocytochemical
staining, and ﬂuorescence resonance energy transfer. Expression of G2L2 increased the intracellular cAMP con-
tent evokedbyA2AR in anA2AR-C-dependentmanner. Immunoprecipitation and pull-down assays demonstrated
that G2L2 selectively bound to A2AR-C and the inactive form of Gαs to facilitate the recruitment of the trimeric G
protein complex to the proximal position of A2AR for efﬁcient activation. Collectively, G2L2 is a new effector that
controls the action of A2AR by modulating its ability to regulate the Gαs-mediated cAMP contents.
© 2013 Published by Elsevier B.V.1. Introduction
Adenosine was shown to play an essential role in modulating
neuronal functions via four adenosine receptors (i.e., A1, A2A, A2B,
and A3), which belong to the seven-transmembrane G-protein-
coupled receptor superfamily [1,2]. Previous studies suggest that the
A2A adenosine receptor (A2AR) is coupled to Gαs and Gαolf in the pe-
ripheral tissues and the striatum, respectively [3,4]. Because A2AR is
colocalized with dopamine D2 receptors (D2R) in enkapherine-
containing GABAergic striatopallidal neurons (i.e., the indirect pathway)
at post-synaptic sites [5], it is a therapeutic target in Parkinson's disease
[6] and Huntington's disease [7]. Ample evidence implicates A2AR in the
regulation of important neuronal functions, including synaptic transmis-
sion and neuronal protection [8–10].
A2AR transmits signals through both G protein-dependent and
-independent pathways. We and others have demonstrated that A2AR
stimulation activates at least two major G protein-dependent signaling
cascades, including adenylyl cyclase (AC)/cAMP/protein kinase A
(PKA)- and PKC-mediated signaling [11,12]. In addition to conventional
G protein-mediated signaling pathways, growing evidence has demon-
strated that the carboxyl terminus of A2AR (A2AR-C) renders it able to
function independently of G proteins [13–15]. Compared to other
adenosine receptors, A2AR contains a relatively long cytoplasmic carboxylces, Academia Sinica, Nankang,
27829143.
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vier B.V.terminus (C-terminus, Fig. 1A) that is highly conserved among species.
Recently, seven interacting proteins were identiﬁed as follows:
(i) α-actinin, which tethers A2AR to the actin cytoskeleton [16]; (ii) a
guanine nucleotide exchange factor of small monomeric G proteins
of the ADP-ribosylation factor (ARF) family (ARNO/cytohesin-2),
which is required for mitogen-activated protein kinase (MAPK)
activation [15]; (iii) calmodulin (CaM), which modulates the
function of A2AR–D2R complexes [17]; (iv) neuronal Ca2+-binding
protein 2 (NECAB2), which retains A2AR in the intracellular compart-
ment and enhances MAPK signaling [18]; (v) a synapse-associated
protein of 102 kDa (SAP102), which reduces the mobility of A2AR
[13]; (vi) translin-X-associated protein (TRAX), which regulates
neuritogenesis [14,19]; and (vii) ubiquitin-speciﬁc protease 4
(USP4), which deubiquitinates A2AR and thus increases the number of
receptors on the plasma membrane [20]. Together with the homo- or
hetero-oligomerization of the receptors, these C-terminus-interacting
proteins form a protein complex named A2AR signalosome. The mecha-
nism depicting how the components within the A2AR signalosome in-
teract has yet to be elucidated.
Growth-arrest-speciﬁc 2-like protein 2 (G2L2) is a protein of 860
amino acids (aa). Its amino acid sequence is conserved among species,
suggesting that its function is evolutionally important. The N terminus
(aa 1–282) of G2L2 shares 60% amino acid similarity with the growth-
arrest-speciﬁc 2 [GAS2, [21]]. AlthoughGAS2was implicated in apoptosis,
membrane rufﬂing, and embryogenesis [22–24], the function of G2L2 re-
mains unclear. Similar to GAS2 [25], G2L2 contains a calponin homology
(CH) domain (aa 1–159) and a GAS2-related (GAR) domain (aa 201–
280), whichmightmediate the binding of G2L2 to the actin cytoskeleton
Fig. 1. G2L2 interacts with A2AR-C. (A) Schematic structure of rat A2AR. (B) HEK293T cells
were transfected with A2AR253–410-ﬂag and G2L2-V5 or TRAX-V5 for 48 h. (C) HEK293T
cells were transfected with G2L2-V5 and the indicated A2AR variant for 48 h. The cells
were collected for immunoprecipitation.↑, N-glycosylation site; ♦, non-speciﬁc bands
appeared in the immunoprecipitated protein complexes. Red arrowheads mark the
A2AR1–410 proteins, while open arrowheads mark those of A2AR1–322.
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deﬁned domain exists in G2L2. There are three paralogs of the
GAS2-related proteins: G2L1, G2L2, and G2L3. All of these proteins
contain the CH and GAR domains and are considered “mini-versions
of spectraplakins” [26]. These GAS2-related proteins therefore might
associate with and/or coordinate various cytoskeletal proteins, in-
cluding microtubules, actin ﬁlaments, and intermediate ﬁlaments
[25–28]. In the present study, we report that G2L2 is a new binding
protein of A2AR-C. In addition, G2L2 regulates the cAMP-elevating
ability of A2AR by recruiting Gsα protein to its proximal location,
for G2L2 is also a novel interacting protein of Gsα. Our study suggeststhat the A2AR-C is crucial for effective stimulation of Gsα-mediated
cAMP signaling by A2AR.
2. Materials and methods
2.1. Reagents and antibodies
Adenosine deaminase (ADA), 50× protease cocktail, and 10×
phosphostop were purchased from Roche (Basel, Switzerland). The
mouse anti-ﬂag monoclonal antibody (mAb) (M2), rabbit anti-actin
polyclonal antibody (pAb), and CGS21680 (CGS) were obtained from
Sigma (St. Louis, MO, USA). The mouse anti-V5 mAb was purchased
from Invitrogen (Carlsbad, CA, USA). The mouse anti-A2AR mAb was
either from Millipore (Bedford, MA, USA) or Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The rabbit anti-A2AR pAb was generated against a
peptide (NH2-VQARVGASSWSSEFAPSC-COOH; Yao-Hong Biotechnology,
Taipei, Taiwan) comprising aa 394–410 of A2AR plus an additional
cysteine residue at its C terminus to facilitate the puriﬁcation of the
resultant antibody. The anti-G2L2-C pAb was generated against a
peptide (NH2-CQEPLKLGGTPLSPEEESWV-COOH) (Yao-Hong Biotechnol-
ogy, Taipei, Taiwan) comprising the last C-terminal 20 amino acids of
G2L2 plus an additional cysteine at the N terminus. The anti-G2L2-N
pAb was generated against a peptide (NH2-VRSIRPFKSSEQYLEC-COOH)
(Angene, Taipei, Taiwan) comprising aa 18–32 of G2L2 plus an additional
cysteine at the C terminus. The mouse anti-myc mAb was obtained from
LTK BioLaboratories (Taipei, Taiwan). The anti-G2L2-D pAb was generat-
ed against the puriﬁed recombinant GST–G2L2579–860 protein (Yao-Hong
Biotechnology). The resultant antiserum (20 ml) was ﬁrst incubated
with GST protein (1 mg) conjugated with glutathione beads (1 ml) to
remove those antibodies that recognized GST. The absorbed anti-
G2L2-D antibody was prepared by incubation with GST–G2L2579–860
coupled to glutathione beads for 16 h at 4 °C. Alexa Flour 488, 568, and
647 and rhodamine–phalloidin were purchased from Molecular Probes
(Eugene, OR, USA).
2.2. Plasmid constructions
All primers employed in the preparation of our constructs are listed
in Supplementary Table S1. The DNA fragments of A2AR1–410, A2AR1–322
were ampliﬁed from rat complementary (c)DNA encoding A2AR [1] by
the polymerase chain reaction (PCR) using speciﬁc primers, and it was
subcloned into the pcDNA3.1/V5-His-TOPO vector (Invitrogen). The
full-length and C-terminus-deleted A2AR-3 × ﬂag constructs were
ampliﬁed by PCR from pcDNA3.1-A2AR1–410 using speciﬁc primers, and
theywere subcloned into the p3X FLAG-CMV14 vector (Sigma). To gener-
ate the A2AR253–410-ﬂag construct, DNA fragments encoding A2AR253–410
[14] were cleaved by Kpn I and Xho I and subcloned into the p3X
FLAG-CMV14 vector. Mouse Gas2-related protein 2 (NM_001013759)
was ampliﬁed by PCR from mouse brain cDNA and subcloned into
pcDNA3.1-V5-His-TOPO. Truncated mutants of G2L2 were ampliﬁed
from the full-length G2L2-V5 fragment (ﬂG2L2-V5) by PCR using spe-
ciﬁc primers, and they were subcloned into pcDNA3.1-V5-His-TOPO.
G2L2–CFP was generated from ﬂG2L2-V5 by a PCR using speciﬁc
primers, digested by Bgl II and Sma I, and then subcloned into the
eCFP vector (Clontech, Palo Alto, CA). The YFP fragment was ampliﬁed
by PCR using speciﬁc primers, digested with Sac II and Xho I, and
subcloned into the pcDNA3-A2AR1–410-V5 to encode the fusion protein
(A2AR-YFP). Expression constructs of the Gα proteins were purchased
from Missouri S&T cDNA Resource Center (Rolla, MO, USA). The DNA
fragments encoding Gαs variants were ampliﬁed by PCR using speciﬁc
primers, cleaved at the Kpn I and Xba I sites, and subcloned into
pcDNA3.1-myc-His (Invitrogen). DNA fragments encoding Gαolf, Gαi,
GαoA, Gαq, or Gα13 were ampliﬁed by PCR using speciﬁc primers,
cleaved at the Kpn I and EcoRV sites, and subcloned into pcDNA3.1-
myc-His (Invitrogen). The AMPK-V5 construct was prepared as previ-
ously described [10]. To generate prokaryotic expression constructs of
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from pcDNA3.1-A2AR1–410 by PCR using speciﬁc primers and subcloned
into pcDNA3.1-V5-His-TOPO (Invitrogen). The resultant constructs
were then cleaved at the Bgl II and Eco RI sites and subcloned into
the Bam HI and Eco RI sites of pGEX-2T (GE Healthcare, Piscataway,
NJ, USA) to produce the recombinant glutathione S-transferase
(GST)-A2AR-C protein. DNA fragments encoding aa 579–860 of
mouse G2L2 were ampliﬁed by PCR using speciﬁc primers, and
subcloned into pET-42a(+) as previously described [29] to produce
recombinant GST–G2L2579–860 proteins. GST–Gαs and -Gαi were
also ampliﬁed from GNA0SL0000 and GNAI100000 by PCR using
speciﬁc primers, and they were subcloned into pET-42a(+). All re-
sultant plasmids were analyzed by nucleotide sequencing to verify
the inserts.
2.3. Cell culture and transfection
HEK-293T cells [human embryonic kidney 293 cells expressing the
large T-antigen of simian virus 40 (SV40)] were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) with 10% fetal bovine serum,
2 mM L-glutamine, 1 mM sodium pyruvate, 1500 mg/l sodium bicar-
bonate, and 1% penicillin/streptomycin (Invitrogen GibcoBRL) with 5%
CO2 at 37 °C. Primary striatal neurons were prepared from Sprague–
Dawley rat brains on embryonic day 18 as described previously [30]
and grown in Neurobasal medium supplemented with B27 (Invitrogen).
Transfection was carried out using Lipofectamine™ 2000 (Invitrogen)
following the manufacturer's protocol.
2.4. In vitro binding
Recombinant GST-fusion proteins were expressed in JM109 (DE3)
and puriﬁed using glutathione-sepharose beads (Promega) following
the manufacturer's protocol. The GST pull-down assay was conducted
by incubating puriﬁed GST fusion proteins with 35S-G2L2 at 4 °C for
2 h in binding buffer (10 mM HEPES at pH 8, 150 mM NaCl, 1 mM
benzamidine, 1% bovine serum albumin (BSA), 0.1% Triton X-100, and
a protease inhibitor cocktail) on a rolling wheel. The bound protein
complexeswere harvested using glutathione-agarose beads, extensively
washed with wash buffer (10 mM HEPES at pH 8, 150 mM NaCl, and
1 mM benzamidine) six times, and separated by a 12% SDS-PAGE,
followed by autoradiography to detect the amount of 35S-labeled G2L2
variant bound by the GST fusion protein (upper panels), and Coomassie
blue staining of SDS-PAGE (bottom panels) to verify the amount of GST
fusion protein loaded.
2.5. Immunoprecipitation
Protein lysates (3 mg) in lysis buffer (20 mMHEPES at pH 8, 2 mM
MgCl2, 1 mM EDTA, 0.5% C12E9, 1 μM MG132, 150 mM NaCl, and a
protease/phosphatase inhibitor cocktail) were incubated with 1 μg
of the indicated antibody coupled to 40 μl of protein A beads
(Sigma-Aldrich) at 4 °C for 2 h on a rolling wheel. After extensive
washing using ice-cold washing buffer (50 mM HEPES, 1 mM
MgCl2, 1 mMEDTA, 0.05% C12E9, 150 mMNaCl, and a protease inhibitor
cocktail), the resultant immunoprecipitation complexes were resolved
in 40 μl of 2× sampling buffer and analyzed by SDS-PAGE and western
blotting.
2.6. FRET assay
HEK293T cells were seeded onto glass-bottom cell culture dishes
(NEST Biotech,Wuxi, China; 1.6 × 104 cells per 20-mmwell), transfected
for 48 h, andmonitored under a confocalmicroscope (LSM510, Carl Zeiss,
Oberkochen, Germany). FRET images were collected following the sensi-
tizing emission protocol per the manufacturer's manual. FRET valueswere calculated and analyzed by the “FRET plus analysis” software in
Aim Image Browser (Carl Zeiss).
2.7. Adenylyl cyclase (AC) assay
HEK293T cells were seeded at a density of 6 × 106 cells per 100-mm
plate, transfected with the indicated DNAs for 24 h, re-plated into two
150-mm plates, and cultured for another 24 h. To remove interference
from endogenous adenosine in the medium, the cells were treated
with adenosine deaminase (ADA, 1 U/ml) in regular culture medium
for 24 h before being harvested. The transfected HEK293T cells were
homogenized using a Sonicator (MISONIX, Farmingdale, New York,
USA) at a setting of output 2 for 30 s. Cell debris and nuclear fragments
were removed by low-speed spinning (1500 ×g for 5 min). For the AC
assay, the collected total lysates (100 μg per reaction unless stated
otherwise) were treated with the indicated reagent for 10 min at
37 °C in a 400-μl reaction mixture containing 1 mM ATP, 100 mM
NaCl, 50 mM HEPES, 21 μM vinpocetine, 20 μM EHNA, 0.7 μM
cilostamide, 20 μM rolipram, 10 μM papaverine, 6 mM MgCl2, 1 μM
GTP, and 0.2 mM EGTA. The reactions were terminated by the addition
of 600 μl of 10% trichloroacetic acid. The cAMP formed was isolated by
Dowex chromatography (Sigma) and assayed by a radioimmunoassay
as described previously [31].
2.8. Immunocytochemistry
The cells were plated onto poly-L-lysine-coated (Sigma) coverslips
and then transfected with the desired construct(s) for 48–72 h. The
cells were ﬁxed with 4% paraformaldehyde in PBS at room temperature
for 30 min, permeabilized with 0.05% NP40/PBS for 10 min, blocked
with PBS/2% BSA/2% goat serum, stained with the desired primary anti-
body reconstituted in PBS/2% BSA at 4 °C for 14–16 h, followed by the
corresponding secondary antibody conjugated with Alexa Fluor-488
and Alexa Fluor-568 at room temperature for 2 h, and analyzed by
laser confocal microscopy (MRC-1000; Bio-Rad, Hercules, CA, USA;
LSM510, Carl Zeiss).
3. Results
3.1. G2L2 interacts with the A2AR-C
To search for novel interacting partners of the A2AR-C (aa 310–
410, Fig. 1A), we generated and puriﬁed a recombinant protein
(GST–A2AR-C) composed of GST fused to the N terminus of A2AR-C.
The puriﬁed GST–A2AR-C was incubated with rat cortical lysates for a
GST pull-down assay as described in “Supplementary methods”. The
identities of those proteins bound to the GST–A2AR-C were determined
bymass spectrometry. Among them, we were particularly interested in
G2L2 (Supplementary material Fig. S1A, C) because functional annota-
tion indicated that this protein might bind to actin cytoskeleton, which
plays an important role in the organization of signaling microdomains.
We noticed that the G2L2 fragments identiﬁed in GST pull-down assays
were much smaller than the predicted size of G2L2 (~95 kDa) and were
likely to be the degradation products of G2L2. Analyses of the peptide
hits revealed the existence of both N- and C- terminal degradation
products of G2L2, suggesting that A2AR-C might associate with large
multiprotein complexes. In addition, G2L2 appeared to be unstable in
the experimental conditions tested. To further investigate the role of
G2L2, we generated an expression construct of mouse G2L2 (which
shares 90% similarity of amino acids with rat G2L2) fused to a V5 tag at
its C terminus. Immunoprecipitation of exogenously expressed G2L2-V5
in HEK293T cells using an anti-V5-antibody or an anti-G2L2 antibody
pulled down both the full-length G2L2 and a small degradation product
of G2L2 (~30 kDa, a C terminal fragment harboring aa 561–572;
Fig. S1B, C), supporting the hypothesis that G2L2 is prone to degradation.
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(A2AR253–410) that contained only the 7th transmembrane span and the
entire A2AR-C [14] was co-transfected into HEK293T cells with G2L2-V5
or another interacting protein of A2AR-C, TRAX-V5 [14] as indicated.
Similar to TRAX-V5, immunoprecipitation of G2L2-V5 brought down
A2AR253–410 (Fig. 1B), supporting the hypothesis that A2AR-C interactedFig. 2.G2L2 directly interacts with A2AR. (A) HEK293T cells transfectedwith G2L2-V5 and A2AR
(purple), and rhodamine–phalloidin (RF, red) to detect F-actin. (B) Primary striatal neurons (da
A2AR antibody (purple), and RF (red). Nuclei were stainedwith Hoechst 33259 (H33258, blue).
est, indicated by squares, are shown in the upper-right corner of the same panel or in a separa
magniﬁcations of the indicated regions shown in the FRET images of (C). Arrows indicate region
YFPweremeasured. (F) GST–A2AR322–410, but not by GST, pulled down G2L2 variants (upper pa
is shown in the lower panel.with G2L2. To identify the domain located on A2AR-C that interacted
with G2L2, we produced a ﬂag-tagged A2AR variant (A2AR1–322-ﬂag)
with a C-terminal truncation. The major immunoreactive bands of these
A2AR variants are consistent with the predicted sizes for A2AR1–410-ﬂag
(WT) and A2AR1–322-ﬂag (46 kDa and 35 kDa, respectively, Fig. 1C).
Each A2AR variant also had a slightly larger species, which was assumed-ﬂagwere ﬁxed and immunostained with the anti-V5 antibody (green), anti-ﬂag antibody
ys in vitro 18)wereﬁxed and immunostainedwith the anti-G2L2-D antibody (green), anti-
Arrows indicate colocalization signals. Higher-magniﬁcation images of the region of inter-
te panel. (C) HEK293T cells were co-transfected with G2L2–CFP and A2AR-YFP. (D) Higher
s that showedpositive FRET values. (E) The FRET values of cells co-transfectedwith CFP and
nel). Coomassie blue staining of the recombinant proteins used in the binding experiments
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the full length A2AR (A2AR1–410). Removal of the C terminal 88 aa of A2AR
(i.e., A2AR1–322) greatly reduced its ability to interact with G2L2 (Fig. 1C).
The domain comprising aa 322–410 of A2AR therefore might be the
major binding site for G2L2.
Immunohistochemical staining showed thatwhen expressed exoge-
nously in HEK293T cells, G2L2-V5 was widely distributed throughout
the cell (Fig. 2A). Consistentwith the above ﬁnding that A2AR interacted
with G2L2, the membrane-associated G2L2-V5 was colocalized with
A2AR (Fig. 2A). Overexpression of A2AR, but not G2L2, alone was sufﬁ-
cient to alter the morphology of HEK293T cells to a round shape. We
next generated an anti-G2L2 antibody (designated anti-G2L2-D) using
a recombinant protein comprising aa 579–860 of G2L2 as the antigen.
The resultant anti-G2L2-D antibody recognized endogenous G2L2 in
the primary striatal neurons, while the anti-G2L2-D antibody absorbed
with the recombinant antigen (G2L2579–860) detected no signal
(Fig. S2). Colocalization of endogenous A2AR and G2L2 was observed
mostly in the neuronal processes. Only very few colocalization signals
were found on the plasma membrane of the soma (Fig. 2B). BecauseFig. 3.Direct interaction is required forG2L2 to enhance the A2AR-mediated adenylyl cyclase (AC)
or G2L2-V5 plus A2AR1–410-V5. (B) The cells were transfected with the vector, G2L2-V5, A2A
G2L21–430-V5, A2AR1–410-V5, or G2L21–430-V5 plus A2AR1–410-V5. Expression levels of G2L2 and
presented as themean ± S.E. from three or four independent experiments. (C) The schematic s
domain of aa 201–280 [25], and a long C-terminal undeﬁned region. (D) PuriﬁedGST and GST–A
Coomassie blue staining of recombinant proteins used in the binding experiments is shown in t
analyzed by western blotting using the anti-G2L2-D (A,B), -N (E), anti-A2AR, and an anti-actinA2AR is known to interact withα-actinin (Fig. S3) [16] and G2L2 contains
a CH domain that binds to the actin cytoskeleton (Fig. S4) [25], we found
that the A2AR/G2L2 complex was associated with cytoskeletal F-actin,
which was stained using rhodamine–phalloidin (Fig. 2A, B). This ﬁnding
is consistentwith the observation that a peptide hit (aa 124–130) located
in the N terminus of G2L2 was found in the GST–A2AR-C pulldown
complex (Fig. S1A, C).
To further assess whether the interaction between A2AR-C and
G2L2 was direct, we generated expression constructs of A2AR-YFP
and G2L2–CFP and transfected these constructs into HEK293T cells for
ﬂuorescence resonance energy transfer (FRET) analyses. If the distance
between A2AR–YFP and G2L2–CFP was less than 100 Å, energy transfer
from the donor (CFP) to the acceptor (YFP) would occur. The images
were pseudocolored with the calculated FRET values accordingly.
Warmer colors represented higher FRET values and shorter distances
between the tested protein pairs. As shown in Fig. 2C, expression of
A2AR–YFP and G2L2–CFP, but not YFP plus CFP (Fig. 2E), together
resulted in positive FRET signals predominantly on cell membranes
(Fig. 2D), which is consistent with the cellular location of A2AR. Thisactivation. (A) HEK293T cellswere transfectedwith an empty vector, G2L2-V5, A2AR1–410-V5,
R1–322-V5, or G2L2-V5 plus A2AR1–322-V5. (E) The cells were transfectedwith the vector,
the A2AR variant were analyzed using western blot analyses (30 μg per lane). The data are
tructure of G2L2 depicts an N-terminal Pfam:CH domain of amino acids (aa) 1–159, a GAR
2AR proteinswere incubatedwith the indicated 35S-G2L2 variant (15 fmol) at 4 °C for 1 h.
he lower panel. * p b 0.001, by one-way ANOVA. The levels of the indicated proteins were
antibody as indicated. ♦, non-speciﬁc bands.
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sufﬁciently close for direct interactions. In addition, the puriﬁed recombi-
nant GST–A2AR322–410 protein, which contains the A2AR-C (aa 322–410)
fused to GST, but not GST alone, successfully pulled down in vitro-
translated G2L2 (Fig. 2F), further demonstrating that A2AR-C directly
interacts with G2L2.
3.2. G2L2 enhanced A2AR-mediated cAMP signaling via direct binding
Many interacting proteins have been reported to bind A2AR, yet only
Usp4 could indirectly control the signaling by preventing membrane
A2AR from recycling into the cytoplasm [20]. As a new binding partner
of A2AR, we overexpressed G2L2 together with A2AR in HEK293T cells to
test whether G2L2 would affect A2AR signaling. This cell line was chosen
because it did not contain a detectable level of endogenous G2L2 protein
using the anti-G2L2-D antibody (Fig. 3). Expression of G2L2 together
with the WT A2AR (i.e., A2AR1–410) enhanced AC activity triggered by
an A2AR-selective agonist (CGS21680, CGS; 10 μM; Fig. 3A). In contrast,
G2L2 did not enhance activation of AC triggered by stimulation of an
A2AR variant that lacked the major binding domain (aa 322–410) of
G2L2 (Figs. 1C, 3B). Therefore, binding with A2AR-C is required to en-
hance A2AR-mediated AC activation by G2L2. Note that the A2AR1–322
preserved most of the functional properties (such as ligand bindingFig. 4. Gαs-2 like 2 (G2L2) selectively bound to the Gαs protein. (A) Puriﬁed GST-Gαi or GS
Coomassie blue staining of the recombinant proteins employed in binding experiments is show
Gα protein for 48 h. The cells were treatedwith ADA (1 U/ml) to remove endogenous adenosin
antibody (1 μg) for immunoprecipitation. Equal volumes of total lysate (1: 100; Input) were loa
and treatedwith adenosine deaminase (ADA, 1 U/ml) andMG132 (10 μM)overnight to preven
a non-speciﬁc band.and the ability to stimulate AC) of the WT A2AR, as previously reported
[32]. Immunocytochemical staining also demonstrated that A2AR1–322
was located properly in the plasma membrane, as did WT A2AR
(Fig. 2A, Supplementary material Fig. S3). To our surprise, expression of
G2L2 caused a slight but statistically signiﬁcant reduction of AC activity
triggered by A2AR1–322 (Fig. 3B), suggesting that an additional factor
might be involved in the regulation of A2AR's activity by G2L2. Another
interesting observation was that the level of exogenously expressed
G2L2 was consistently lower in the presence of A2AR variants (including
A2AR1–410 and A2AR1–322), which activated the Gαs/AC/cAMP pathways
upon stimulation (Fig. 3). The protein level of G2L2 thus might be regu-
lated by a cAMP-dependent pathway.
G2L2 contains two cytoskeleton-associated domains (i.e., CH and
GAR) at its N terminus and a highly variable C terminal domain with
no similarity to other known protein domains (Fig. 3C). To search for
the A2AR-interacting domain of G2L2, we created a series of G2L2
mutants as follows: G2L2201–860, which had no CH domain, G2L2281–860,
which had neither the CH nor the GAR domain, G2L21–430, and
G2L2431–860. These G2L2 variants were in vitro translated and labeled
with 35S-methionine (Fig. S5). In the GST pull-down assays, the recom-
binant GST–A2AR-C protein pulled down all G2L2 variants except
G2L21–430. The A2AR binding domain of G2L2 therefore was located at
its C terminus (aa 431–860, Fig. 3D). Consistently, a peptide hitT–Gαs proteins (15 μg) were incubated with 35S-labeled G2L2 (30 fmol) at 4 °C for 1 h.
n in the lower panel. (B) HEK293T cells were transfected with G2L2-V5 and the indicated
e for 24 h before being harvested. The cell lysates (3 mg)were incubatedwith the anti-V5
ded as a control. (C) HEK293T cells were transfectedwith the indicated constructs for 48 h
t interference by endogenous adenosine receptors anddegradation of G2L2, respectively.♦,
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down from brain lysate using GST–A2AR-C (Fig. S1A, C). In line with
this conclusion, expression of a G2L2 variant (G2L21–430), which did
not bind A2AR, did not affect A2AR-mediated activation of AC (Fig. 3E).
This result further strengthened our hypothesis that direct binding
between G2L2 and A2AR is critical for the enhancement of A2AR's signal
by G2L2.
3.3. G2L2 is a novel interacting protein of Gαs
Although G2L2 enhanced A2AR-mediated AC activation as described
above (Fig. 3A), forskolin (10 μM)-evokedAC activity did not signiﬁcantly
differ in the absence or presence of G2L2 (Fig. S6, 100.0 ± 1.4 and
102.02 ± 5.7, respectively, mean ± SEM, n = 11; p = 0.401, Student's
t-test). Because forskolin directly activates ACs [33] and G2L2 did not
alter the cAMP response triggered by forskolin, we reasoned that G2L2
might mediate its enhancing effect on A2AR's cAMP signaling by altering
the coupling between A2AR and Gαs. Given the importance of the local
microdomain concentration of the targeted protein(s) in the cAMPFig. 5. Inactive formof Gαs competedwith A2AR to bind to the C-terminus of G2L2. (A, C, E) HEK
(1 U/ml) overnight before being harvested. The immunocomplexes were analyzed by western
amount of Gαs was normalized to that of immunoprecipitated G2L2 in each condition and wa
from three independent experiments. * p b 0.001, by Student's t-test. (D) Quantiﬁcation o
immunoprecipitated G2L2 in each condition and was compared to those in the presence of
* p b 0.05, by one-way ANOVA.signaling pathway [34,35], we tested whether G2L2 also interacted
with Gαs. As shown in Fig. 4A, the interaction between G2L2 and
Gαs appeared to be direct because puriﬁed GST–Gαs (but not GST-Gαi)
successfully pulled down the in vitro-translated 35S-labeled G2L2.
We next examined whether G2L2 selectively bound to Gαs by co-
expression of different Gα isoforms and G2L2 in HEK293T cells, followed
by immunoprecipitation and western blot analyses as shown in Fig. 4B.
Among the six Gα proteins tested, G2L2 selectively bound to Gαs,
Gαolf, Gαq, and Gα13. No binding of G2L2 with Gαi or GαoA was de-
tected. Since A2AR may also be coupled to G proteins other than Gαs
[36,37], the potential binding to Gαq/Gα13 raised the possibility that
G2L2 might also facilitate other Gα protein-mediated signaling path-
ways triggered by A2AR.
3.4. The inactive form of Gαs competed with the A2AR and bound to the
C-terminus of G2L2
Immunoprecipitation of Gαs coexpressed with the indicated G2L2
variant in HEK293T cells indicated that Gαs bound the C terminus of293T cells were transfectedwith the indicated constructs for 48 h and incubatedwith ADA
blotting. ♦, a non-speciﬁc band. (B) Quantiﬁcation of the level of Gαs bound to G2L2. The
s compared with those in the absence of A2AR. The data are presented as the mean ± S.E.
f the level of A2AR bound to G2L2. The amount of A2AR was normalized to that of
Gαs-WT. The data are presented as the mean ± S.E. from 3 independent experiments.
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of G2L2 (Fig. 3D), we tested whether A2AR and Gαs could bind to G2L2
in a competitive manner. Elevated expression of A2AR in HEK293T cells
signiﬁcantly reduced the amount of Gαs bound by G2L2 (Fig. 5A, B).
Most importantly, we found that expression of the dominant negative
Gsα mutant, which binds xanthine nucleotides instead of guanine
nucleotides (Q227L/D295N,Gαs-X; [38]), but not the dominant positive
Gsαmutantwith reduced GTPase activity (Gsα-Q227L, [39]), of Gαs re-
duced the interaction between G2L2 and A2AR (Fig. 5C, D) due to the
preferential binding of G2L2 to the inactive Gαs (Fig. 5E). Collectively,
these data showed that binding sites of A2AR-C and Gαs both existed
in the C terminus of G2L2 and likely overlapped. G2L2 might facilitate
the recruitment of trimeric G protein complexes to the proximal
position of A2AR for efﬁcient assembly of the G protein with A2AR upon
stimulation (Fig. 6). Once stimulated by activated A2AR, the GTP-bound
Gαs protein would be released from the C terminus of G2L2 to activate
its downstream effectors, while the empty C terminus of G2L2 would
then be recruited by A2AR-C until its next encounter with inactive Gαs
proteins.
4. Discussion
In the present study, we identiﬁed G2L2 as a novel scaffold protein
that directly binds to A2AR-C and the inactive form of Gαs. Because
G2L2 has a CH domain at its N terminus as does GAS2 (Fig. 3C, [25]), it
is colocalizedwith F-actin, as revealed by immunocytochemical analysis
(Figs. 2A, B, S4). Similarly, A2AR also colocalizes with F-actin (Fig. S3)
because it tethers to the cytoskeleton via direct binding to an F-actin
cross-linking protein (α-actinin, [16]) at its C terminus (aa 291–322 of
A2AR). Even without the direct interaction between A2AR-C and G2L2 as
shown in the present study (Figs. 1–3), A2ARwould have the opportunity
to indirectly co-localize with G2L2 through binding to α-actinin/F-actin
(Figs. 2A, B, S3, 4). Nonetheless, G2L2 did not enhance the activation of
AC evoked by A2AR1–322, the A2AR variant that lacked the major G2L2-
binding site but contained an intact α-actinin-binding site and therefore
was tethered to F-actin (Figs. 3B, S3). The G2L2 variant (G2L21–430),
which contained the CH domain and thus bound to F-actin (Fig. S4), did
not increase the activation of AC evoked by A2AR either (Fig. 3E). G2L2
therefore is unlikely to modulate those G-protein-coupled receptors
(GPCRs) that are bound to the cytoskeleton [40–43] unless they also
directly bind to G2L2, as was observed for A2AR. Our data showed that
the C terminus of G2L2 preferentially bound to the inactive form of Gαs
(Fig. 5C, E) and facilitated the efﬁcient assembly of trimeric G proteinFig. 6.A schematic representation showingG2L2 as a novel scaffolding protein that recruits com
with F-actin, whereas the A2AR also colocalized with F-actin via α-actinin (α). The C terminus
protein complex to the proximal position of A2AR for efﬁcient activation (A). Once activated by a
its downstream effectors (B), while the empty C terminus of G2L2 was then recruited by A2ARcomplexes with A2AR upon stimulation (Fig. 6). Via binding to G2L2,
A2AR-C controls an appropriate and effective microdomain environment
and thus enhances stimulation of Gαs and activation of its downstream
effectors (such as AC, Fig. 3A). Our data collectively suggest that the
synergistic interplay among A2AR, Gsα, and G2L2 is critical for enhance-
ment of A2AR's signal. In addition, such facilitation of A2AR's signal highly
depends on the physical interaction between A2AR and G2L2. The
Gsα-binding site of the A2AR variant (A2AR1–322) that did not bind
to G2L2 remained intact and could activate Gsα andAC upon stimulation
(Fig. 3B). Expression of G2L2, another Gsα-binding protein, is likely to
compete for available Gsα proteins with A2AR1–322, and thus suppressed
AC activity evoked by A2AR1–322 (Fig. 3B). Likewise, removal of the
A2AR-interacting domain (aa 431–860) of G2L2 also eliminated the
enhancing effect of G2L2 on AC activation triggered by A2AR
(Fig. 3E). We noted that expression of G2L21–430 also slightly reduced
A2AR's signal, although the difference was too small to be statistically
signiﬁcant (Fig. 3E). While G2L21–430 lacks the A2AR-binding site, its
CH domain is intact and therefore is associated with the F-actin cyto-
skeleton (Figs. 3C, S4). It is possible that G2L21–430 might function as a
dominant negative mutant to compete with the endogenous wildtype
G2L2 for an association with the cytoskeleton, and therefore might
compromise the enhancing function of endogenous G2L2. Nonetheless,
because we did not detect endogenous G2L2 in HEK293T cells, the level
of endogenous G2L2 in HEK293T cells might have been too low to
produce any impact on our experimental observations. This would
also explain why the effect of G2L21–430 on A2AR's signal was not signif-
icant (Fig. 3E). Alternatively, the slight decrease in A2AR's signal by
G2L21–430 might have been due to nonspeciﬁc alteration of the cytoskel-
etal structure due to overexpression of a cytoskeleton-binding protein
(G2L21–430). Taken together, these results suggest that the direct interac-
tion between A2AR and G2L2 is essential for constructing a microdomain
that favors activation of Gαs by A2AR.
In addition to being coupled to Gαs and Gαolf, A2AR was reported to
trigger signaling pathways via other G proteins [37,44]. Because G2L2
also bound to Gαq and Gα12/13 (Fig. 4B), G2L2 might also modulate
A2AR-triggered signals other than cAMP. It is unlikely that other mem-
bers of the GAS2 family also possess similar functions to G2L2 because
their homologous regions are mostly in the N-terminus [21,25,26,45],
not in their C-terminal domains, which usually exert distinct functions
[45] (Fig. S7). It should be noted that human G2L2 was previously
reported to exist in HEK293T cells [25]. However, our in-house anti-
G2L2-D antibody, which was raised against a recombinant protein con-
taining the most variable C terminus of mouse G2L2 (aa 579–860),ponents of A2AR signalosome to themicroenvironment. TheN terminus ofG2L2 colocalized
of G2L2 bound to the inactive form of Gαs to facilitate the recruitment of the trimeric G
denosine, the GTP-boundGαs proteinwas released from the C terminus of G2L2 to activate
-C until its next encounter with inactive Gαs proteins (C).
3153Y.-C. Wu et al. / Biochimica et Biophysica Acta 1833 (2013) 3145–3154failed to detect the presence of endogenous human G2L2 in HEK293T
cells (Fig. 3). This discrepancymost likely occurred because of the highly
variable C-terminus of mouse G2L2, which shares only 66% amino acid
similarity (Fig. S8) with that of human G2L2.
To date, at least 8 proteins (including G2L2) that interact with the C
terminus of A2AR have been reported and characterized [13–16,20].
Among them, G2L2 is the ﬁrst A2AR-interacting partner that directly
contributes to the A2AR-mediated cAMP signaling pathway. Such an en-
hancing effect of G2L2 on A2AR relies on the direct binding between
A2AR and G2L2, which contributes to the formation of a microdomain
that favors the activation of Gαs by A2AR. Because Gαs-activated
cAMP signaling is the major pathway that mediates the functions of
A2AR [10,46], G2L2 might serve as a key determinant that controls the
action of A2AR by modulating its ability to regulate the cellular cAMP
contents. Because G2L2 binds to the same domain of A2AR as does D2R
[47], the potential role of G2L2 in A2AR–D2R heteromerization is also
of great interest. In addition to direct intra-membrane interactions, an
important intracellular electrostatic interaction occurred between the
N-terminus of the 3rd intracellular loop of D2R (i.e., the Arg-rich epitope)
and the C-terminal segment of A2AR (aa 370–378 in humans; aa 365–373
in the rat) that overlaps with the G2L2-binding domain (aa 322–410,
Fig. 1C).Moreover, twoArg-rich regions exist in the A2AR-binding domain
of G2L2 (576ALRRREQAL585 and 759LRPRIRPRRD768; the Arg-rich regions
are underlined), supporting G2L2 possibly competing with D2R for
A2AR. This is particularly important because our data showed that G2L2
bound to Gαolf (Fig. 4B), which is the major Gαs-like protein in the
striatum where A2AR and D2R colocalize [5]. It is possible that G2L2
might interfere with A2AR–D2R heteromerization and facilitate the
A2AR/Gαolf-mediated cAMP signal in the striatum. In addition to poten-
tially interfering with the physical interaction between A2AR and D2R,
the “biochemical ﬁngerprint” of the A2AR–D2R heteromer including
ligand binding afﬁnity, G protein coupling switch, and receptor in-
ternalization [48], might also be affected by G2L2 and is worth fur-
ther evaluation in the future. Given that A2AR drugs were implicated
in neuronal neurodegenerative diseases [9,46,49–52], further charac-
terization of the expression and subcellular localization of G2L2 during
development and degenerative disorders would greatly advance our
current understanding of A2AR as a drug target for neuronal diseases
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